vs
Ascendis Pharma A/S（ASND）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
Ascendis Pharma A/S的季度营收约是Ultragenyx Pharmaceutical Inc.的1.3倍（$267.3M vs $207.3M），Ascendis Pharma A/S同比增速更快（42.3% vs 25.9%），过去两年Ascendis Pharma A/S的营收复合增速更高（60.7% vs 38.0%）
Ascendis Pharma A/S是一家聚焦内分泌疾病治疗领域的生物制药企业，核心业务覆盖生长激素疗法的研发、生产与商业化。其依托重组DNA技术生产的生长激素类处方药物，可用于治疗多种生长激素缺乏相关适应症，临床应用场景广泛。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
ASND vs RARE — 直观对比
营收规模更大
ASND
是对方的1.3倍
$207.3M
营收增速更快
ASND
高出16.4%
25.9%
两年增速更快
ASND
近两年复合增速
38.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $267.3M | $207.3M |
| 净利润 | — | $-128.6M |
| 毛利率 | 90.5% | — |
| 营业利润率 | — | -54.7% |
| 净利率 | — | -62.0% |
| 营收同比 | 42.3% | 25.9% |
| 净利润同比 | — | 3.5% |
| 每股收益（稀释后） | — | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ASNDRARE
| Q4 25 | $267.3M | $207.3M | ||
| Q3 25 | $230.7M | $159.9M | ||
| Q2 25 | $170.7M | $166.5M | ||
| Q1 25 | $109.0M | $139.3M | ||
| Q4 24 | $187.8M | $164.6M | ||
| Q3 24 | $62.5M | $139.5M | ||
| Q2 24 | $38.9M | $147.0M | ||
| Q1 24 | $103.6M | $108.8M |
净利润ASNDRARE
| Q4 25 | — | $-128.6M | ||
| Q3 25 | $-65.9M | $-180.4M | ||
| Q2 25 | $-42.0M | $-115.0M | ||
| Q1 25 | $-102.2M | $-151.1M | ||
| Q4 24 | — | $-133.2M | ||
| Q3 24 | $-107.1M | $-133.5M | ||
| Q2 24 | $-118.1M | $-131.6M | ||
| Q1 24 | $-141.5M | $-170.7M |
毛利率ASNDRARE
| Q4 25 | 90.5% | — | ||
| Q3 25 | 89.5% | — | ||
| Q2 25 | 80.1% | — | ||
| Q1 25 | 82.6% | — | ||
| Q4 24 | 91.9% | — | ||
| Q3 24 | 80.6% | — | ||
| Q2 24 | 68.2% | — | ||
| Q1 24 | 92.1% | — |
营业利润率ASNDRARE
| Q4 25 | — | -54.7% | ||
| Q3 25 | 5.1% | -106.9% | ||
| Q2 25 | -33.5% | -64.8% | ||
| Q1 25 | -103.2% | -102.6% | ||
| Q4 24 | — | -74.3% | ||
| Q3 24 | -167.3% | -94.6% | ||
| Q2 24 | -370.2% | -79.1% | ||
| Q1 24 | -51.2% | -151.9% |
净利率ASNDRARE
| Q4 25 | — | -62.0% | ||
| Q3 25 | -28.5% | -112.8% | ||
| Q2 25 | -24.6% | -69.0% | ||
| Q1 25 | -93.7% | -108.5% | ||
| Q4 24 | — | -80.9% | ||
| Q3 24 | -171.5% | -95.7% | ||
| Q2 24 | -303.9% | -89.5% | ||
| Q1 24 | -136.6% | -156.8% |
每股收益（稀释后）ASNDRARE
| Q4 25 | — | $-1.28 | ||
| Q3 25 | — | $-1.81 | ||
| Q2 25 | — | $-1.17 | ||
| Q1 25 | — | $-1.57 | ||
| Q4 24 | — | $-1.34 | ||
| Q3 24 | — | $-1.40 | ||
| Q2 24 | — | $-1.52 | ||
| Q1 24 | — | $-2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $665.3M | $421.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $-175.8M | $-80.0M |
| 总资产 | $1.4B | $1.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ASNDRARE
| Q4 25 | $665.3M | $421.0M | ||
| Q3 25 | $582.2M | $202.5M | ||
| Q2 25 | $533.6M | $176.3M | ||
| Q1 25 | $559.4M | $127.1M | ||
| Q4 24 | $604.3M | $174.0M | ||
| Q3 24 | $675.6M | $150.6M | ||
| Q2 24 | $279.4M | $480.7M | ||
| Q1 24 | $345.9M | $112.3M |
股东权益ASNDRARE
| Q4 25 | $-175.8M | $-80.0M | ||
| Q3 25 | $-188.0M | $9.2M | ||
| Q2 25 | $-202.6M | $151.3M | ||
| Q1 25 | $-205.0M | $144.2M | ||
| Q4 24 | $-114.2M | $255.0M | ||
| Q3 24 | $-105.1M | $346.8M | ||
| Q2 24 | $-346.8M | $432.4M | ||
| Q1 24 | $-257.2M | $140.3M |
总资产ASNDRARE
| Q4 25 | $1.4B | $1.5B | ||
| Q3 25 | $1.2B | $1.2B | ||
| Q2 25 | $1.2B | $1.3B | ||
| Q1 25 | $1.1B | $1.3B | ||
| Q4 24 | $1.3B | $1.5B | ||
| Q3 24 | $1.2B | $1.5B | ||
| Q2 24 | $819.0M | $1.6B | ||
| Q1 24 | $866.7M | $1.3B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $58.2M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | — | $-100.8M |
| 自由现金流率自由现金流/营收 | — | -48.6% |
| 资本支出强度资本支出/营收 | — | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-472.0M |
8季度趋势，按日历期对齐
经营现金流ASNDRARE
| Q4 25 | $58.2M | $-99.8M | ||
| Q3 25 | — | $-91.4M | ||
| Q2 25 | — | $-108.3M | ||
| Q1 25 | $-15.5M | $-166.5M | ||
| Q4 24 | $-330.7M | $-79.3M | ||
| Q3 24 | — | $-67.0M | ||
| Q2 24 | — | $-77.0M | ||
| Q1 24 | $-109.7M | $-190.7M |
自由现金流ASNDRARE
| Q4 25 | — | $-100.8M | ||
| Q3 25 | — | $-92.7M | ||
| Q2 25 | — | $-110.7M | ||
| Q1 25 | — | $-167.8M | ||
| Q4 24 | — | $-79.5M | ||
| Q3 24 | — | $-68.6M | ||
| Q2 24 | — | $-79.0M | ||
| Q1 24 | — | $-193.9M |
自由现金流率ASNDRARE
| Q4 25 | — | -48.6% | ||
| Q3 25 | — | -58.0% | ||
| Q2 25 | — | -66.5% | ||
| Q1 25 | — | -120.5% | ||
| Q4 24 | — | -48.3% | ||
| Q3 24 | — | -49.2% | ||
| Q2 24 | — | -53.7% | ||
| Q1 24 | — | -178.2% |
资本支出强度ASNDRARE
| Q4 25 | — | 0.5% | ||
| Q3 25 | — | 0.8% | ||
| Q2 25 | — | 1.5% | ||
| Q1 25 | — | 1.0% | ||
| Q4 24 | — | 0.1% | ||
| Q3 24 | — | 1.2% | ||
| Q2 24 | — | 1.4% | ||
| Q1 24 | — | 3.0% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ASND
暂无分部数据
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
